Metformin Revisited

Abstract

The explosive increase in the prevalence of type 2 diabetes (T2D) in recent decades has been paralleled by an almost equally dramatic increase in the number of therapeutic agents available for treating this condition. However, in spite of the development of several new classes of antidiabetes agents in recent years, metformin remains the firstline pharmacotherapeutic option for most cases of T2D, as per most national and international guidelines.1,2 It also finds use as an adjunct to insulin in gestational diabetes and diabetes complicating pregnancy.